Mirum Pharmaceuticals Inc [MIRM] stock is trading at $59.97, up 0.25%. An important factor to consider is whether the stock is rising or falling in short-term value. The MIRM shares have gain 15.28% over the last week, with a monthly amount glided 13.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stifel started tracking the stock with Buy rating on April 17, 2024, and set its price target to $48. On December 18, 2023, H.C. Wainwright reiterated its Buy rating and revised its price target to $58 on the stock. Morgan Stanley initiated its recommendation with a Overweight and recommended $60 as its price target on November 13, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 24, 2023, and assigned it a price target of $50.
Mirum Pharmaceuticals Inc [MIRM] stock has fluctuated between $36.86 and $61.00 over the past year. Currently, Wall Street analysts expect the stock to reach $57.25 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $59.97 at the most recent close of the market. An investor can expect a potential drop of -4.54% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Mirum Pharmaceuticals Inc [NASDAQ:MIRM] reported sales of 429.16M for the trailing twelve months, which represents a growth of 64.09%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.25 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Mirum Pharmaceuticals Inc’s Current Ratio is 3.13. On the other hand, the Quick Ratio is 2.97, and the Cash Ratio is 1.58. Considering the valuation of this stock, the price to sales ratio is 7.02, the price to book ratio is 11.77.
Transactions by insiders
Recent insider trading involved Howe Jolanda, SVP, GLOBAL CONTROLLER, that happened on Aug 07 ’25 when 10000.0 shares were sold. CHIEF EXECUTIVE OFFICER, Peetz Christopher completed a deal on Aug 07 ’25 to sell 40000.0 shares. Meanwhile, Officer JOLANDA MARIE HOWE bought 10000.0 shares on Aug 07 ’25.
